Search Results - joost+oppenheim

4 Results

Sort By:

Polypeptides for Stimulation of Immune Response (Adjuvants)

Abstract: HMGN polypeptides belong to the high mobility group (HMG) family of chromosomal binding peptides. HMGN polypeptides typically function inside the cell nucleus to bind to DNA and nucleosomes and regulate the transcription of various genes. HMGN polypeptides also can be released by peripheral blood mononuclear cells. However, the extracellular...

Published: 5/22/2024 | Inventor(s): De Yang, Joost Oppenheim, Michael Bustin

Keywords(s): Autoimmune, HMGN, immune response, immunoadjuvant, POLYPEPTIDES, Vaccine Adjuvant

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Oncology

Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1

Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer. However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer. For those cancers associated with these limited immune systems, there remains a need...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, De Yang, Michael Bustin

Keywords(s): Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy

Abstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs,...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, Dimiter Dimitrov, De Yang, Xin Chen, Zhongyu Zhu

Keywords(s): ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration